对接受间歇性化疗的骨髓瘤患者环磷酰胺处置情况的反复研究。
Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy.
作者信息
Edwards G, Calvert R T, Crowther D, Bramwell V, Scarffe H
出版信息
Br J Clin Pharmacol. 1980 Sep;10(3):281-5. doi: 10.1111/j.1365-2125.1980.tb01756.x.
Abstract
1 The disposition of cyclophosphamide was investigated in a group of myeloma patients. 2 Marked changes in clearance and volume of distribution of cyclophosphamide occurred between investigations. 3 The observed changes in disposition did not correlate with biochemical estimates of renal and hepatic function or plasma protein status.
摘要
对一组骨髓瘤患者的环磷酰胺处置情况进行了研究。
在各次研究之间，环磷酰胺的清除率和分布容积发生了显著变化。
观察到的处置变化与肾和肝功能的生化评估或血浆蛋白状态无关。
相似文献
1
Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy.对接受间歇性化疗的骨髓瘤患者环磷酰胺处置情况的反复研究。
Br J Clin Pharmacol. 1980 Sep;10(3):281-5. doi: 10.1111/j.1365-2125.1980.tb01756.x.
2
The disposition of cyclophosphamide in a group of myeloma patients.环磷酰胺在一组骨髓瘤患者中的处置情况。
Cancer Chemother Pharmacol. 1979;3(4):253-9. doi: 10.1007/BF00254741.
3
Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.浆细胞骨髓瘤：美法仑耐药患者对大剂量间歇性环磷酰胺的反应
Can Med Assoc J. 1972 Nov 4;107(9):851-5.
4
[Treatment of multiple myeloma. High-dose intermittent administration of cyclophosphamide and prednisolone--follow up study of 10 years period].
Gan To Kagaku Ryoho. 1983 Nov;10(11):2286-91.
5
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.皮下注射与静脉注射硼替佐米用于新诊断多发性骨髓瘤的两种不同诱导治疗：前瞻性GMMG-MM5试验的中期分析
Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.
6
Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure.
Bone Marrow Transplant. 2000 Sep;26(6):685-8. doi: 10.1038/sj.bmt.1702592.
7
Effect of liver failure on the pharmacokinetics of cyclophosphamide.肝衰竭对环磷酰胺药代动力学的影响。
Eur J Clin Pharmacol. 1984;26(5):591-3. doi: 10.1007/BF00543491.
8
[Urticaria reaction after intravenous administration of cyclophosphamide in 2 patients with multiple myeloma].[2例多发性骨髓瘤患者静脉注射环磷酰胺后出现荨麻疹反应]
Rev Med Interne. 1987 Mar-Apr;8(2):208-9. doi: 10.1016/s0248-8663(87)80174-1.
9
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.比较挽救性输注化疗方案治疗复发性/难治性多发性骨髓瘤。
Cancer. 2015 Oct 15;121(20):3622-30. doi: 10.1002/cncr.29533. Epub 2015 Jul 6.
10
[Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
Arzneimittelforschung. 1980;30(9):1588-92.
引用本文的文献
1
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.乳腺癌患者中环磷酰胺生物活化的遗传药理学。
Cancer Chemother Pharmacol. 2021 Sep;88(3):533-542. doi: 10.1007/s00280-021-04307-0. Epub 2021 Jun 10.
2
Clinical pharmacokinetics of cyclophosphamide.环磷酰胺的临床药代动力学
Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003.
3
Pharmacokinetic drug interactions of commonly used anticancer drugs.常用抗癌药物的药代动力学药物相互作用。
Clin Pharmacokinet. 1986 May-Jun;11(3):223-35. doi: 10.2165/00003088-198611030-00004.
4
Clinical pharmacokinetics of cyclophosphamide.环磷酰胺的临床药代动力学
Clin Pharmacokinet. 1991 Mar;20(3):194-208. doi: 10.2165/00003088-199120030-00002.
5
Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients.
Cancer Chemother Pharmacol. 1992;30(3):207-11. doi: 10.1007/BF00686313.
本文引用的文献
1
The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo.苯巴比妥或2-二乙氨基乙基-2,2-二苯基戊酸酯对环磷酰胺体内活化的影响。
J Pharmacol Exp Ther. 1972 Feb;180(2):475-83.
2
Clinical pharmacology of cyclophosphamide.环磷酰胺的临床药理学
Cancer Res. 1973 Feb;33(2):226-33.
3
Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.生物样本中环磷酰胺和异环磷酰胺的定量气相色谱法测定
J Pharm Sci. 1974 Oct;63(10):1554-8. doi: 10.1002/jps.2600631014.
4
Statistical estimations in pharmacokinetics.药物动力学中的统计学估计
J Pharmacokinet Biopharm. 1974 Apr;2(2):123-48. doi: 10.1007/BF01061504.
5
Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.大鼠肝脏微粒体对环磷酰胺激活作用的酶学基础。
J Pharmacol Exp Ther. 1970 Aug;174(2):206-10.
6
The effect of phenobarbital on cyclophosphamide antitumor activity.苯巴比妥对环磷酰胺抗肿瘤活性的影响。
Cancer Res. 1976 Aug;36(8):2785-9.
7
Commentary: a physiological approach to hepatic drug clearance.述评：肝脏药物清除的生理学方法
Clin Pharmacol Ther. 1975 Oct;18(4):377-90. doi: 10.1002/cpt1975184377.
8
The serum level approach to individualization of drug dosage.药物剂量个体化的血清水平法。
Eur J Clin Pharmacol. 1975 Oct 10;9(1):1-8. doi: 10.1007/BF00613423.
9
Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.采用气相色谱-化学电离质谱法对接受环磷酰胺治疗的患者血浆和尿液中环磷酰胺、磷酰胺氮芥和去甲氮芥进行定量分析。
Cancer Res. 1978 Feb;38(2):408-15.
10
Cyclophosphamide, vincristine and sequential split-course radiotherapy in the treatment of small cell lung cancer.环磷酰胺、长春新碱及序贯分段放疗治疗小细胞肺癌
Chest. 1975 Jun;67(6):675-9. doi: 10.1378/chest.67.6.675.
Zotero 插件